SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Elderly woman consulting female doctor at desk with computer
Opinion
Adopting a patient-centric approach is a competitive advantage
Bringing patients into the drug development process early has proven to save time, money and resources.
April 14, 2026
 · 
4 min read
 · 
Charlotte Moser
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Antibody-drug conjugate (ADC)
BioNTech, DualityBio tout ‘clinically meaningful’ efficacy for ADC in mid-stage endometrial cancer trial
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.
April 13, 2026
 · 
2 min read
 · 
Tristan Manalac
Aerial view of cargo ship terminal
Manufacturing
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. have at least one key starting material with a single source country, according to a new report from United States Pharmacopeia.
April 13, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Hand pointing upward with growth arrow. Business success and positive progress.
Lymphoma
Allogene stock sails after CAR T clears residual lymphoma in early data cut
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
April 13, 2026
 · 
3 min read
 · 
Gabrielle Masson
light bulb shot up through the concrete floor.,Thinking Beyond the Box and Going Beyond Expectations,performance beyond expectations,3d rendering
Pancreatic cancer
Revolution rises 40% as pancreatic cancer drug doubles survival
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
April 13, 2026
 · 
2 min read
 · 
Annalee Armstrong
Futuristic Cyber Abstracy Eye Background 4K
Cancer
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy
Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
April 13, 2026
 · 
2 min read
 · 
Heather McKenzie
Man with neck and back ache vector stock illustration
Pain
AbbVie enters world of pain in up to $715M deal with China’s Haisco
The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.
April 13, 2026
 · 
1 min read
 · 
Annalee Armstrong
Indoor boxing ring corner with flooding spotlight .
Radiopharmaceuticals
Regeneron enters radiopharma ring with up to $4.3B Telix alliance
Telix is Regeneron’s entry ticket into the radiopharma game, helping to better round out the company’s cancer portfolio, according to Truist Securities.
April 13, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing businessman trying to create his own road
Complete response letters
Second rejection for tumor destroyer puts Replimune on a ‘challenging path’
Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.
April 13, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS